Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Voyager Therapeutics (VYGR) Stock Price & Analysis

VYGR Stock Chart & Stats

MX$30.00-MX$5.00(-14.29%)
At close:
Mex$63Mex$63.5Mex$6429 Apr18 May
Day’s Range
MXN 30.00 - MXN 30.00
52-Week Range
MXN 30.00 - MXN 93.00
Previous Close
MXN 35.00
Volume
0
Average Volume (3M)
0
Market Cap
MXN 1.99B
Enterprise Value
MXN 128.15M
Total Cash (Recent Filing)
MXN 116.34M
Total Debt (Recent Filing)
MXN 32.57M
Price to Earnings (P/E)
―
Beta
-0.44
Next Earnings
Nov 10, 2026 (Est.)
EPS Estimate
-7.87
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

CNS Delivery Platform

Voyager’s specialized AAV capsid and CNS delivery capabilities provide a focused technological foundation for its genetic-medicine pipeline. If these tools translate into effective, targeted treatment delivery, they can support multiple neurological programs and create durable platform value beyond a single product.

Manageable Leverage

Debt remains moderate relative to equity for a biotechnology company, limiting the immediate burden from borrowing and preserving some financial flexibility. This balance-sheet structure is a relative strength while Voyager works to advance programs, although continued losses are reducing the underlying equity cushion.

Leadership Continuity

The planned leadership transition combines an incoming executive with operational and finance experience at Sanofi Genzyme and within Voyager with continued board involvement from the outgoing CEO. That combination may support execution continuity as the company advances its Alzheimer’s program.

Bears Say

Revenue Contraction

The sharp, multi-period revenue decline indicates that Voyager’s current commercial or partnered revenue base has weakened materially. Lower revenue reduces internal funding capacity and increases reliance on successful pipeline progress, future partnerships, or external financing to support ongoing operations.

Accelerating Cash Burn

Voyager’s accelerating operating cash outflow raises the importance of maintaining adequate funding while clinical and preclinical programs progress. Persistent burn can reduce strategic flexibility, shorten the period supported by existing resources, and increase dependence on financing or other capital sources.

Losses And Shrinking Equity

The move from strong profitability in 2023 to sizable losses in later periods is eroding the company’s capital base. Continued negative returns and declining equity weaken resilience, leaving less balance-sheet capacity to absorb setbacks or sustain investment if losses persist.

Voyager Therapeutics News

VYGR FAQ

What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was Mex$30.00 and its highest was Mex$93.00 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Voyager Therapeutics’s market cap is Mex$1.99B.
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s next earnings report is estimated for Nov 10, 2026 (not yet confirmed), which is in 8 days.
How were Voyager Therapeutics’s earnings last quarter?
Voyager Therapeutics released its earnings results on Aug 06, 2026. The company reported -Mex$7.517 earnings per share for the quarter, beating the consensus estimate of -Mex$9.095 by Mex$1.579.
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate is -7.87.
How many shares outstanding does Voyager Therapeutics have?
Voyager Therapeutics has 61,617,947 shares outstanding.
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Voyager Therapeutics reported an EPS of -Mex$7.517 in its last earnings report, beating expectations of -Mex$9.095. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Voyager Therapeutics?
Hedge funds hold Voyager Therapeutics shares: hedge funds decreased their holdings by 194.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology